<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816074</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0189</org_study_id>
    <nct_id>NCT01816074</nct_id>
  </id_info>
  <brief_title>Sequencing Treatments for Mothers With ADHD and Their At - Risk Children</brief_title>
  <acronym>TMF</acronym>
  <official_title>Sequencing Treatments for Mothers With ADHD and Their At - Risk Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that successfully treating maternal Attention Deficit Hyperactivity Disorder
      (ADHD) will have a beneficial effect that extends to the child. We believe that
      multi-component interventions combining maternal stimulant medication, Lisdexamfetamine
      (LDX), and Behavioral Parent Training (BPT) will improve parenting, maternal, and child
      outcomes. In terms of improved parenting, we hypothesize that some mothers may respond well
      to LDX or BPT alone and therefore may not require multi-modal treatment, whereas others may
      benefit most from multi-modal treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overarching goal of this study is to construct and evaluate an adaptive intervention
      (i.e., an individualized treatment protocol that is adjusted based on the child-mother dyad's
      initial response to treatment) to improve the trajectory of ADHD outcomes in at-risk
      children. Our primary outcome measure for the child will be whether child ADHD symptoms on
      the Conners Parent and Teacher Rating Scales decreased at the completion of the study. Our
      secondary outcome measure will be whether there was a need for medication for the child over
      the course of the study. The primary outcome for the mother will be the Conners Adult ADHD
      Rating Scale (CAARS) Attention Scale and the Clinical Global Impression-Severity scale
      (CGI-S).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">May 1, 2017</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Child Behavioral Functioning</measure>
    <time_frame>Assessed for the duration of study participation, an expected average of 16 weeks.</time_frame>
    <description>Child symptom severity will be assessed using the Clinical Global Impression - Severity (CGI-s) scale. This was collected at Baseline, Week 8 (end of Phase 1) and Week 16 (end of Phase 2). The CGI-S scale summarizes the clinician's impression of the participant's symptom improvement and ranges from 1-7 with 1 representing very much improved and 7 representing very much worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal Behavioral Functioning</measure>
    <time_frame>Mothers will be assessed for the duration of their participation, an expected average of 16 weeks.</time_frame>
    <description>The Clinical Global Impression - Severity (CGI-S) scale will be used. This was collected at Baseline, Week 8 (end of Phase 1) and Week 16 (end of Phase 2). The CGI-S scale summarizes the clinician's impression of the participant's symptom improvement and ranges from 1-7 with 1 representing very much improved and 7 representing very much worse.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Parental and Family Functioning</measure>
    <time_frame>Assessed for the duration of the study participation, up to 16 weeks</time_frame>
    <description>The Dyadic Parent-Child Interaction Coding System (DPICS) will be used at baseline, week 8, and week 16 to provide an observational measure of positive and negative behaviors of the mother toward the child. Instances of positive (e.g. praise) and negative (e.g. criticism) behaviors are coded by study raters trained to reliability; scores range from 0 to no upper limit. Higher numbers indicate higher instances of the observed behaviors.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Maternal Medication then meds</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to enhanced medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BPT then continued beh tx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to enhanced behavioral treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maternal Medication then BPT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to combined treatment (adding Behavior Parent Training).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BPT then maternal medication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to active ADHD medication, Vyvanse.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vyvanse (lisdexamphetamine)</intervention_name>
    <description>Active ADHD drug, Vyvanse, is administered to mother.</description>
    <arm_group_label>Maternal Medication then meds</arm_group_label>
    <arm_group_label>Maternal Medication then BPT</arm_group_label>
    <arm_group_label>BPT then maternal medication</arm_group_label>
    <other_name>Lisdexamfetamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavior Parent Training</intervention_name>
    <description>Mother is given 8 weeks of individual sessions of behavioral parent training</description>
    <arm_group_label>BPT then continued beh tx</arm_group_label>
    <arm_group_label>Maternal Medication then BPT</arm_group_label>
    <arm_group_label>BPT then maternal medication</arm_group_label>
    <other_name>BPT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Mothers Inclusion Criteria:

          -  Sign informed consent

          -  Be between 21-50 years old (inclusive) at the screening visit and English-speaking

          -  At screening (after washout, if required) meet full Diagnostic and Statistical Manual
             (DSM-IV) criteria for ADHD, any subtype

          -  Have current CGI-S-ADHD rating &gt; 4 and &lt; 8

          -  Have findings on physical exam (PE), laboratory studies, vital signs, and
             electrocardiogram (ECG) judged to be normal for age with no contraindications for
             methylphenidate (MPH) treatment

          -  Have pulse and blood pressure (BP) within 95% of age and gender mean

          -  Commit to the entire visit schedule for the study

          -  Be able to complete all study assessments

          -  Women of childbearing potential (not surgically sterile or post-menopausal) must agree
             to use a medically-accepted contraception method consistently

          -  Mothers with comorbid mood/anxiety disorders which are effectively treated with
             Selective Serotonin Reuptake Inhibitors (SSRIs) will be eligible for participation,
             provided this medication has not changed within 30 days, is well tolerated, and that
             current mood symptoms are not severe or associated with active suicidal ideation.
             Also, the prescribing physician must approve of their participation in the study.

        Mothers Exclusion Criteria:

          -  History of allergic reactions or severe negative response to study medications

          -  History of alcohol/substance abuse in the past 3 months or a positive urinary toxic
             screen on initial evaluation that is not explained by a time-limited medical
             circumstance

          -  History of or current bipolar illness, schizophrenia, psychoses, or significant
             suicidal risk

          -  History of chronic or acute medical disorder for which stimulant therapy would be
             contraindicated (e.g., glaucoma, hypertension)

        Child Inclusion Criteria:

          -  Sign assent if older than 6

          -  Be between the ages of 4-8

          -  symptoms of ADHD (Conners Hyperactivity Index &gt; 60), no prior treatment with effective
             doses of stimulants, defined as one or more weeks of treatment with adequate doses.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Stein, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2013</study_first_submitted>
  <study_first_submitted_qc>March 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2013</study_first_posted>
  <results_first_submitted>April 18, 2018</results_first_submitted>
  <results_first_submitted_qc>April 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2018</results_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Mark Stein</investigator_full_name>
    <investigator_title>Professor/Director</investigator_title>
  </responsible_party>
  <keyword>Mothers</keyword>
  <keyword>ADHD</keyword>
  <keyword>Treatment</keyword>
  <keyword>Child</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eligible participants were recruited from the investigators' practices, clinic referrals, online advertisements, and radio advertisements. Participants were enrolled between September 2012 and December 2016.</recruitment_details>
      <pre_assignment_details>7 participants didn't meet inclusion criteria, 1 decided not to participate after screening, 2 withdrew due to time commitment issues, 1 had a comorbid psychiatric disorder, 1 had a physical contraindication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Maternal Medication Then Additional Maternal Medication</title>
          <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to enhanced medication
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.</description>
        </group>
        <group group_id="P2">
          <title>Maternal Behavioral Parent Training (BPT) Then Additional BPT</title>
          <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to enhanced behavioral treatment.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
        </group>
        <group group_id="P3">
          <title>Maternal Medication Then BPT</title>
          <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to combined treatment (adding Behavior Parent Training).
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
        </group>
        <group group_id="P4">
          <title>BPT Then Maternal Medication</title>
          <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to active ADHD medication, Vyvanse.
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Time commitment issues</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Time commitment Issues</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfied with Randomization assignmen</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>We enrolled a total of 53 mother-child dyads (total of 106 participants), 41 dyads were randomized to a treatment arm and completed the baseline visit (total of 82 participants). The number of participants in this section is double that of the participant flow because the dyads are split to accurately analyze characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>Maternal Medication Then Meds</title>
          <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to enhanced medication
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.</description>
        </group>
        <group group_id="B2">
          <title>BPT Then Continued Beh tx</title>
          <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to enhanced behavioral treatment.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
        </group>
        <group group_id="B3">
          <title>Maternal Medication Then BPT</title>
          <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to combined treatment (adding Behavior Parent Training).
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
        </group>
        <group group_id="B4">
          <title>BPT Then Maternal Medication</title>
          <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to active ADHD medication, Vyvanse.
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>41 dyads were randomized to treatment and completed a baseline visit. The dyads are separated to analyze the baseline characteristics: moms and children. This means that there are a total of 41 moms and 41 children for a total of 82 participants.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Mom age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.55" spread="7.31"/>
                    <measurement group_id="B2" value="39.00" spread="5.94"/>
                    <measurement group_id="B3" value="37.82" spread="5.78"/>
                    <measurement group_id="B4" value="41.00" spread="6.73"/>
                    <measurement group_id="B5" value="39.59" spread="6.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Child age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.00" spread="1.73"/>
                    <measurement group_id="B2" value="5.89" spread="1.05"/>
                    <measurement group_id="B3" value="6.18" spread="1.47"/>
                    <measurement group_id="B4" value="6.60" spread="1.35"/>
                    <measurement group_id="B5" value="6.17" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <population>41 dyads were randomized to treatment and completed a baseline visit. The dyads are separated to analyze the baseline characteristics: moms and children. This means that there are a total of 41 moms and 41 children for a total of 82 participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Child gender</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parent gender</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>41 dyads were randomized to treatment and completed a baseline visit. The dyads are separated to analyze the baseline characteristics: moms and children. This means that there are a total of 41 moms and 41 children for a total of 82 participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Mom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Child</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>41 dyads were randomized to treatment and completed a baseline visit. The dyads are separated to analyze the baseline characteristics: moms and children. This means that there are a total of 41 moms and 41 children for a total of 82 participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Mother Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Child Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Child Behavioral Functioning</title>
        <description>Child symptom severity will be assessed using the Clinical Global Impression - Severity (CGI-s) scale. This was collected at Baseline, Week 8 (end of Phase 1) and Week 16 (end of Phase 2). The CGI-S scale summarizes the clinician's impression of the participant's symptom improvement and ranges from 1-7 with 1 representing very much improved and 7 representing very much worse.</description>
        <time_frame>Assessed for the duration of study participation, an expected average of 16 weeks.</time_frame>
        <population>7 participants had missing data, the Child CGI-S was not collected at any of the study visits for these participants because they completed the study before this measure was added to the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal Medication Then Additional Maternal Medication</title>
            <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to enhanced medication
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.</description>
          </group>
          <group group_id="O2">
            <title>Maternal Behavioral Parent Training (BPT) Then Additional BPT</title>
            <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to enhanced behavioral treatment.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
          </group>
          <group group_id="O3">
            <title>Maternal Medication Then BPT</title>
            <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to combined treatment (adding Behavior Parent Training).
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
          </group>
          <group group_id="O4">
            <title>BPT Then Maternal Medication</title>
            <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to active ADHD medication, Vyvanse.
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
          </group>
        </group_list>
        <measure>
          <title>Child Behavioral Functioning</title>
          <description>Child symptom severity will be assessed using the Clinical Global Impression - Severity (CGI-s) scale. This was collected at Baseline, Week 8 (end of Phase 1) and Week 16 (end of Phase 2). The CGI-S scale summarizes the clinician's impression of the participant's symptom improvement and ranges from 1-7 with 1 representing very much improved and 7 representing very much worse.</description>
          <population>7 participants had missing data, the Child CGI-S was not collected at any of the study visits for these participants because they completed the study before this measure was added to the protocol.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" spread="0.92"/>
                    <measurement group_id="O2" value="4.56" spread="1.42"/>
                    <measurement group_id="O3" value="4.44" spread="0.96"/>
                    <measurement group_id="O4" value="4.67" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="0.67"/>
                    <measurement group_id="O2" value="3.75" spread="1.09"/>
                    <measurement group_id="O3" value="3.63" spread="0.99"/>
                    <measurement group_id="O4" value="3.78" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.13" spread="0.93"/>
                    <measurement group_id="O2" value="3.67" spread="1.25"/>
                    <measurement group_id="O3" value="3.38" spread="1.22"/>
                    <measurement group_id="O4" value="3.22" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Behavioral Functioning</title>
        <description>The Clinical Global Impression - Severity (CGI-S) scale will be used. This was collected at Baseline, Week 8 (end of Phase 1) and Week 16 (end of Phase 2). The CGI-S scale summarizes the clinician's impression of the participant's symptom improvement and ranges from 1-7 with 1 representing very much improved and 7 representing very much worse.</description>
        <time_frame>Mothers will be assessed for the duration of their participation, an expected average of 16 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maternal Medication Then Additional Maternal Medication</title>
            <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to enhanced medication
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.</description>
          </group>
          <group group_id="O2">
            <title>Maternal Behavioral Parent Training (BPT) Then Additional BPT</title>
            <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to enhanced behavioral treatment.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
          </group>
          <group group_id="O3">
            <title>Maternal Medication Then BPT</title>
            <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to combined treatment (adding Behavior Parent Training).
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
          </group>
          <group group_id="O4">
            <title>BPT Then Maternal Medication</title>
            <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to active ADHD medication, Vyvanse.
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Behavioral Functioning</title>
          <description>The Clinical Global Impression - Severity (CGI-S) scale will be used. This was collected at Baseline, Week 8 (end of Phase 1) and Week 16 (end of Phase 2). The CGI-S scale summarizes the clinician's impression of the participant's symptom improvement and ranges from 1-7 with 1 representing very much improved and 7 representing very much worse.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" spread="0.64"/>
                    <measurement group_id="O2" value="4.50" spread="0.50"/>
                    <measurement group_id="O3" value="4.82" spread="0.72"/>
                    <measurement group_id="O4" value="4.45" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.55" spread="0.50"/>
                    <measurement group_id="O2" value="3.67" spread="0.67"/>
                    <measurement group_id="O3" value="2.60" spread="0.66"/>
                    <measurement group_id="O4" value="3.80" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" spread="0.60"/>
                    <measurement group_id="O2" value="3.86" spread="0.35"/>
                    <measurement group_id="O3" value="2.60" spread="1.02"/>
                    <measurement group_id="O4" value="2.56" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Parental and Family Functioning</title>
        <description>The Dyadic Parent-Child Interaction Coding System (DPICS) will be used at baseline, week 8, and week 16 to provide an observational measure of positive and negative behaviors of the mother toward the child. Instances of positive (e.g. praise) and negative (e.g. criticism) behaviors are coded by study raters trained to reliability; scores range from 0 to no upper limit. Higher numbers indicate higher instances of the observed behaviors.</description>
        <time_frame>Assessed for the duration of the study participation, up to 16 weeks</time_frame>
        <population>6 participants were in the study before this assessment was added. 2 participants did not complete this assessment before they withdrew from the study. 3 participants withdrew from the study after the baseline visit (1 in the medication then medication arm after week 8, 1 in the Medication then BPT arm and 1 in BPT then BPT arm).</population>
        <group_list>
          <group group_id="O1">
            <title>Maternal Medication Then Additional Maternal Med - Baseline</title>
            <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to enhanced medication
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.</description>
          </group>
          <group group_id="O2">
            <title>Maternal Medication Then Additional Maternal Med - Week 8</title>
            <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to enhanced medication
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.</description>
          </group>
          <group group_id="O3">
            <title>Maternal Medication Then Additional Maternal Med - Week 16</title>
            <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to enhanced medication
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.</description>
          </group>
          <group group_id="O4">
            <title>Maternal Medication Then Behavior Parent Training - Baseline</title>
            <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to combined treatment (adding Behavior Parent Training).
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
          </group>
          <group group_id="O5">
            <title>Maternal Medication Then Behavior Parent Training - Week 8</title>
            <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to combined treatment (adding Behavior Parent Training).
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
          </group>
          <group group_id="O6">
            <title>Maternal Medication Then Behavior Parent Training - Week 16</title>
            <description>The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to combined treatment (adding Behavior Parent Training).
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
          </group>
          <group group_id="O7">
            <title>Behavior Parent Training Then Maternal Medication - Baseline</title>
            <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to active ADHD medication, Vyvanse.
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
          </group>
          <group group_id="O8">
            <title>Behavior Parent Training Then Maternal Medication - Week 8</title>
            <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to active ADHD medication, Vyvanse.
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
          </group>
          <group group_id="O9">
            <title>Behavior Parent Training Then Maternal Medication - Week 16</title>
            <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to active ADHD medication, Vyvanse.
Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
          </group>
          <group group_id="O10">
            <title>Behavior Parent Training Then Additional BPT - Baseline</title>
            <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to enhanced behavioral treatment.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
          </group>
          <group group_id="O11">
            <title>Behavior Parent Training Then Additional BPT - Week 8</title>
            <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to enhanced behavioral treatment.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
          </group>
          <group group_id="O12">
            <title>Behavior Parent Training Then Additional BPT - Week 16</title>
            <description>The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to enhanced behavioral treatment.
Behavior Parent Training: Mother is given 8 weeks of individual sessions of behavioral parent training</description>
          </group>
        </group_list>
        <measure>
          <title>Parental and Family Functioning</title>
          <description>The Dyadic Parent-Child Interaction Coding System (DPICS) will be used at baseline, week 8, and week 16 to provide an observational measure of positive and negative behaviors of the mother toward the child. Instances of positive (e.g. praise) and negative (e.g. criticism) behaviors are coded by study raters trained to reliability; scores range from 0 to no upper limit. Higher numbers indicate higher instances of the observed behaviors.</description>
          <population>6 participants were in the study before this assessment was added. 2 participants did not complete this assessment before they withdrew from the study. 3 participants withdrew from the study after the baseline visit (1 in the medication then medication arm after week 8, 1 in the Medication then BPT arm and 1 in BPT then BPT arm).</population>
          <units>instances observed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Positive Parenting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.61" spread="13.70"/>
                    <measurement group_id="O2" value="27.17" spread="12.39"/>
                    <measurement group_id="O3" value="32.56" spread="16.75"/>
                    <measurement group_id="O4" value="41.67" spread="26.03"/>
                    <measurement group_id="O5" value="31.55" spread="19.73"/>
                    <measurement group_id="O6" value="51.70" spread="25.04"/>
                    <measurement group_id="O7" value="21.83" spread="13.93"/>
                    <measurement group_id="O8" value="46.33" spread="28.65"/>
                    <measurement group_id="O9" value="44.07" spread="46.78"/>
                    <measurement group_id="O10" value="17.49" spread="10.48"/>
                    <measurement group_id="O11" value="34.71" spread="14.65"/>
                    <measurement group_id="O12" value="39.52" spread="20.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Negative Parenting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.33" spread="11.36"/>
                    <measurement group_id="O2" value="17.01" spread="12.79"/>
                    <measurement group_id="O3" value="10.51" spread="10.80"/>
                    <measurement group_id="O4" value="8.64" spread="5.19"/>
                    <measurement group_id="O5" value="13.47" spread="14.58"/>
                    <measurement group_id="O6" value="5.96" spread="5.32"/>
                    <measurement group_id="O7" value="8.04" spread="6.77"/>
                    <measurement group_id="O8" value="5.01" spread="4.74"/>
                    <measurement group_id="O9" value="7.66" spread="6.64"/>
                    <measurement group_id="O10" value="10.64" spread="6.28"/>
                    <measurement group_id="O11" value="9.44" spread="4.48"/>
                    <measurement group_id="O12" value="8.85" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks. Adverse events were collected from participants while they were in the study. Adverse events were not collected from participants that were not currently on medication including the BPT then BPT arm and the BPT then Medication arm while in the BPT phase.</time_frame>
      <desc>At each weekly visit, the parent met with the investigators and research staff. Investigators inquired about any side effects the parent experienced and recorded responses.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vyvanse 20 mg</title>
          <description>Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother. For the mothers that were randomized to medication arm, 20mg was the first dose they received.</description>
        </group>
        <group group_id="E2">
          <title>Vyvanse 30 mg</title>
          <description>Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother. For the mothers that were randomized to medication arm, 30mg was offered to the mother if 20mg was not a strong enough dose.</description>
        </group>
        <group group_id="E3">
          <title>Vyvanse 40mg</title>
          <description>Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother. For the mothers that were randomized to medication arm, 40mg was offered to the mother if 30mg was not a strong enough dose.</description>
        </group>
        <group group_id="E4">
          <title>Vyvanse 50 mg</title>
          <description>Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother. For the mothers that were randomized to medication arm, 50mg was offered to the mother if 40mg was not a strong enough dose.</description>
        </group>
        <group group_id="E5">
          <title>Vyvanse 60 mg</title>
          <description>Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother. For the mothers that were randomized to medication arm, 60mg was offered to the mother if 50mg was not a strong enough dose.</description>
        </group>
        <group group_id="E6">
          <title>Vyvanse 70mg</title>
          <description>Vyvanse (lisdexamphetamine): Active ADHD drug, Vyvanse, is administered to mother. For the mothers that were randomized to medication arm, 70mg was offered to the mother if 60mg was not a strong enough dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Events</sub_title>
                <description>Includes events such as elevated BP, racing heart, thumping heart, etc.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite Suppression</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrointestinal issues</sub_title>
                <description>Includes GI slowing, constipation, GERD, stomachaches</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sleep Disturbance or Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Jitteriness/Restlessness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Illness/Infection</sub_title>
                <description>Includes colds, influenza, upper respiratory infection, urinary tract infection, etc.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Increased Menstraul Cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tense</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Scotomata</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark Stein</name_or_title>
      <organization>Dept of Psychiatry, University of Washington</organization>
      <phone>206-987-1161</phone>
      <email>mstein42@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

